We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Citoxlab Group, a non-clinical CRO, has entered into a definitive agreement to acquire Solvo Biotechnology, a CRO specializing in drug transporter studies and the assessment of Drug-Drug Interactions (DDI).